Bioregenx (BRGX) Accumulated Expenses (2023 - 2026)

Bioregenx's Accumulated Expenses history runs 4 years deep, the most recent figure standing at $605510.0 for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 31.71% year-over-year to $605510.0; the TTM figure through Mar 2026 stood at $605510.0 (up 31.71% YoY), while the FY2025 annual figure was $434370.0, up 2.38% from the prior year.
• Accumulated Expenses was $605510.0 for Q1 2026 at Bioregenx, up from $434370.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $605510.0 in Q1 2026 to a low of $346677.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $424413.0 across 4 years, with a median of $414886.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses decreased 10.81% in 2025, then soared 31.71% in 2026.
• A 4-year view of Accumulated Expenses shows it stood at $346677.0 in 2023, then increased by 22.38% to $424277.0 in 2024, then gained by 2.38% to $434370.0 in 2025, then surged by 39.4% to $605510.0 in 2026.
• The last three Accumulated Expenses figures came in at $605510.0 (Q1 2026), $434370.0 (Q4 2025), and $380599.0 (Q3 2025), per Business Quant data.